
A breakthrough treatment strategy for resistant melanomas involves checkpoint kinase 1 (CHK1) inhibitor combined with low-dose hydroxyurea (LDHU). This approach effectively targets replication stress, triggering an immune response in both BRAF inhibitor (BRAFi)-resistant and immune checkpoint inhibitor (ICI)-resistant melanomas, mirroring the immune response of parental tumors.
Like
Save
Share